Section Arrow
Quote
SLBT.NASDAQ
- SL Science Holding Limited
Quotes are at least 15-min delayed:2026/11/04 17:03 EST
After Hours
Last
 1.11
0 (0.00%)
Bid
1.13
Ask
1.22
High 1.11 
Low 1.11 
Volume 0 
Regular Hours (Closed)
Last
 1.11
-0.11 (-9.02%)
Day High 
1.22 
Prev. Close
1.22 
1-M High
1.75 
Volume 
39.58K 
Bid
1.13
Ask
1.22
Day Low
1.1 
Open
1.2 
1-M Low
1.02 
Market Cap 
684.13M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.24 
20-SMA 1.38 
50-SMA 1.84 
52-W High 14.5 
52-W Low 1.02 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.01/--
Enterprise Value
684.19M
Balance Sheet
Book Value Per Share
0.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CRISCuris Inc.1.11+0.3961+55.48%0.2PE
After Hours 1.05 -0.06 -5.41%
KPTIKaryopharm Therapeutics Inc.0.0729-0.0154-17.44%-- 
After Hours 0.0761 +0.0032 +4.39%
GERNGeron Corp1.08+0.15+16.13%-- 
After Hours 1.07 -0.01 -0.93%
INOInovio Pharmaceuticals1.62-0.04-2.41%-- 
After Hours 1.6115 -0.0085 -0.52%
RXRXRecursion Pharmaceuticals3.88+0.2+5.43%-- 
After Hours 3.8608 -0.0192 -0.49%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. Itoperates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.